Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood …
Full NVO analysis →
Competitive advantage assessment
Key strengths
Margins Consistently Above PeersGross margin at 81.0% (top 11%) and operating margin at 41.3% (top 0%) indicate strong pricing power.
Margins Stable Across CyclesOperating margin volatility is low (stability score 0.94), demonstrating pricing resilience across cycles.
Key risks
Liquidity ConcernsLiquidity is concerning (score 0.21), raising questions about short-term obligations.
The dashed ring is the peer median. Defense scores are percentile ranks
against peers, so 50 is roughly the typical company in this group.
Upgrade to unlock the signals and evidence behind each defense.
Premium access
Unlock full defense analysis
Get key signals, strengths, and risks for every moat dimension.
Novo Nordisk A/S ranks #1 of 20
scored companies in Drug Manufacturers - General by moat score — the top 5%.
That makes it the widest moat in the group.
Moat scores for companies ranked near NVO in Drug Manufacturers - General
Pricing power is the ability to raise prices without losing volume.
Cost Advantage
Score 78
· 15% of the moat score
A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.
Customer Stickiness
Score 54
· 15% of the moat score
Stickiness is what makes revenue repeat without being re-won every year.
Capital Efficiency
Score 66
· 18% of the moat score
Capital efficiency asks what the company earns on the money tied up in the business.
Resilience
Score 64
· 17% of the moat score
Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.
Scale & Market Position
Score 80
· 15% of the moat score
Scale matters only when it converts into economics.
Novo Nordisk A/S (NVO) scores 74 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #1 of 20 scored companies in Drug Manufacturers - General, the top 5%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 19 companies in Drug Manufacturers - General. Its strongest defense is Pricing Power (94/100) and its weakest is Customer Stickiness (54/100).
How does Novo Nordisk A/S compare with other Drug Manufacturers - General companies?
Novo Nordisk A/S ranks #1 of 20 scored companies in Drug Manufacturers - General by moat score. That is the widest moat in Drug Manufacturers - General. The companies ranked closest are Novartis AG (NVS) at 72 just below it.
How is the moat score calculated?
Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 19 companies in Drug Manufacturers - General. The defenses are then weighted to produce the overall score out of 100.
Why is Novo Nordisk A/S scored with the Corporate Default template?
Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.
Which competitive defenses are measured for Novo Nordisk A/S?
The Corporate Default template measures 6 defenses, and NVO scores: Pricing Power (94), Cost Advantage (78), Customer Stickiness (54), Capital Efficiency (66), Resilience (64), Scale & Market Position (80). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.
We value your privacy
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking 'Accept All', you consent to our use of cookies.
Read our cookie policy
Cookie Preferences
Manage your cookie preferences. Essential cookies are always enabled.